The effect of dapagliflozin on renal function in patients with type 2 diabetes.
about
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy.Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol.Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis
P2860
Q32186373-B67940C0-741F-4A49-A006-5F586F18E07BQ33625568-B3A091F4-F455-4BB0-A678-E9484466D18AQ33731855-CA507CE7-9B01-4876-978C-85DD011D5C88Q37588847-41C9B3BD-F261-4FB2-9CFA-9044CCB40FE5Q38870752-97ADA3CC-D793-4578-A2F0-0B6F7F3F8E79Q38906041-BEF14809-C20E-4EEF-99A0-B54AC2496773Q38932322-04741767-D08A-44C9-A22C-0A2485D6B9E8Q38940175-6A28D74F-34E1-43EA-9756-D233C726CEA1Q39039079-42971EE1-B3A3-4D52-9F53-52E4704AE191Q39170860-C339B2B9-15A7-4E0A-8F5D-915540F47CDDQ39290337-5566FCCD-DF95-4146-97AC-F7A87FB04B48Q47115045-EDD5BA94-DDCD-4A8E-9214-410D3BF0427CQ47769540-4FFFB1A2-9E42-4303-BA4E-EE96B4A44CD1Q47918474-38C71C0C-AE79-410B-9DFC-5469452A98ECQ55669037-58711888-3A1A-463D-A677-85BF9FD7C966Q58123825-C9D6443F-8EC8-4CF1-B046-1542104E3E04
P2860
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@en
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@nl
type
label
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@en
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@nl
prefLabel
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@en
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@nl
P2093
P2860
P1476
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
@en
P2093
Agata Ptaszynska
Donald Elliott Kohan
Kristina Johnsson
Paola Fioretto
Shamik Parikh
P2860
P2888
P304
P356
10.1007/S40620-016-0261-1
P577
2016-02-19T00:00:00Z